Activation of interferon regulatory factor 3 by replication-competent Vaccinia viruses improves antitumor efficacy mediated by T-cell responses by Riederer, Stephanie et al.
Original ArticleActivation of interferon regulatory factor 3 by
replication-competent vaccinia viruses improves
antitumor efficacy mediated by T cell responses
Stephanie Riederer,1 Robert Fux,1 Michael H. Lehmann,1 Asisa Volz,1,2 Gerd Sutter,1,2 and Juan J. Rojas1,3
1Division of Virology, Department of Veterinary Sciences, LMU Munich, 80539 Munich, Germany; 2German Center for Infection Research (DZIF), Partner Site Munich,
80539 Munich, Germany; 3Department of Pathology and Experimental Therapies, IDIBELL, University of Barcelona, 08907 L’Hospitalet de Llobregat, SpainReceived 17 December 2020; accepted 1 June 2021;
https://doi.org/10.1016/j.omto.2021.06.001.
Correspondence: Gerd Sutter, Division of Virology, Department of Veterinary
Sciences, LMU Munich, Veterinärstrasse 13, 80539 Munich, Germany.
E-mail: gerd.sutter@lmu.deRecently, oncolytic vaccinia viruses (VACVs) have shown their
potential to provide for clinically effective cancer treatments.
The reason for this clinical usefulness is not only the direct
destruction of infected cancer cells but also activation of im-
mune responses directed against tumor antigens. For eliciting
a robust antitumor immunity, a dominant T helper 1 (Th1) cell
differentiation of the response is preferred, and such polariza-
tion can be achieved by activating the Toll-like receptor 3
(TLR3)-interferon regulatory factor 3 (IRF3) signaling
pathway. However, current VACVs used as oncolytic viruses
to date still encode several immune evasion proteins involved
in the inhibition of this signaling pathway. By inactivating
genes of selected regulatory virus proteins, we aimed for a
candidate virus with increased potency to activate cellular anti-
tumor immunity but at the same time with a fully maintained
replicative capacity in cancer cells. The removal of up to three
key genes (C10L,N2L, and C6L) fromVACV did not reduce the
strength of viral replication, both in vitro and in vivo, but re-
sulted in the rescue of IRF3 phosphorylation upon infection
of cancer cells. In syngeneic mouse tumor models, this activa-
tion translated to enhanced cytotoxic T lymphocyte (CTL)
responses directed against tumor-associated antigens and
neo-epitopes and improved antitumor activity.
INTRODUCTION
During the last two decades, the understanding of the relationship be-
tween cancer and the immune system has considerably changed, and
implemented the role of the immune system controlling tumorigenesis
and tumor progression.1,2 Cancer immunotherapies aim tomobilize the
immune system to kill cancer cells and represent a revolution in cancer
therapeutics: the field has seen outstanding progress in the last decade,
showing unprecedented clinical responses. However, challenges arise
for immunotherapies when treating a larger range of cancer types,
mostly due to the complexity of the immune contexture and varying tu-
mor immunogenicity.3,4 Antibody-mediated blockade of immune
checkpoints5–7 and chimeric antigen receptor (CAR) T cells8–10 have
spearheaded this revolution, but a large number of novel modalities
are being developed showing potential in preclinical and clinical trials.
Further improvement of these novel immunotherapies is urgently
needed to achieve clinical responses in currently resistant tumors.Molecular Ther
This is an open access article under tVirotherapy uses genetically modified or naturally occurring viruses
for the lysis of tumor cells. However, clinical data have demonstrated
that these so-called oncolytic viruses primarily act as immunother-
apies: viral replication serves as an extremely potent danger signal
for the immune system within the tumor, allows overcoming tumor
immunosuppression, and induces cytotoxic T lymphocyte (CTL) re-
sponses targeting a multitude of tumor antigens released by viral
replication.11,12 Among the various candidate viruses, vaccinia virus
(VACV), the prototype human live virus vaccine used to eradicate
smallpox,13 displays several advantages as an oncolytic vector,
including a fast and lytic replication cycle, an excellent human safety
record, and high capacity for harboring transgenes.14 Importantly,
VACVs are highly immunogenic, and the targeted deletion of
VACV genes can further improve this immunogenicity, transforming
VACVs into useful tools for activating potent antitumor immune
responses.15
Robust anti-tumor CTL responses have been shown to play a key
role in the successful treatment of cancer.16 In cancer vaccination,
the use of the Toll-like receptor 3 (TLR3) agonist polyinosinic-pol-
ycytidylic acid (poly(I:C)) as an adjuvant has been shown to in-
crease the number of CTLs targeting tumor antigens.17 TLR3
activation leads to interferon (IFN) regulatory factor 3 (IRF3)
phosphorylation and consequently to expression of type I IFNs,
which correlates directly with increased levels of CTLs.18–20 Inter-
estingly, type I IFNs also play a crucial role in anti-VACV defense;
that is, VACVs encode several proteins (including C10, A46, N2,
or C6) that antagonize the TRL3-IRF3 signaling pathway at
different levels.21 As a result, phosphorylation of IRF3 is efficiently
inhibited in VACV-infected cells, but deletions in some of these
genes, such as C6 or N2, proved to improve CD8 T cell responses
in vaccination strategies.22,23 In addition, MVA (modified VACV
Ankara), a highly attenuated strain of VACV with genomic muta-
tions and deletions that inactivate many immunomodulatoryapy: Oncolytics Vol. 22 September 2021 ª 2021 The Author(s). 399
he CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Generation of oncolytic VACV with
deletions in key genes blocking activation of the
IRF3 signaling pathway
(A) Schematic diagram of VACV genomes indicating the
positions of the viral genes targeted by sequential dele-
tion. For the prospect of monitoring viral replication, an
expression cassette encoding the red fluorescent marker
protein mCherry was inserted into the thymidine kinase
(J2R) site of the virus genomes. (B) PCR analysis to
confirm deletions in target genes. Expected size of the
PCR products are as follows: C10L = 1,311 bp, DC10L =
692 bp; N2L = 1,126 bp, DN2L = 670 bp; C6L =
1,083 bp, DC6L = 682 bp.
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infection.24,25 However, the particular genetics of MVA are associ-
ated with a defective replication in mammalian cells, which greatly
reduces its capacity for use as an oncolytic agent.26–29 Thus, the
generation of oncolytic VACV combining the capacity to activate
the TLR3-IRF3 pathway with an efficient replication in cancer cells
represents a major step toward an efficient VACV-based oncolytic
therapy.
In this study, we constructed a battery of oncolytic VACVs by
combining deletions in key VACV genes involved in the inhibition
of IRF3 activation. We evaluated their replication competence in can-
cer cells as well as their ability to elicit T cell responses against tumor
neo-antigens, demonstrating the feasibility to obtain replication-effi-
cient VACVs with an increased capacity to activate the IRF3 pathway.
Importantly, these modifications translated into improved treatments
in mouse tumor models.
RESULTS
Generation of oncolytic VACV with deletions in key genes
blocking activation of the IRF3 pathway
To improve cellular immune responses, we modified the candidate
oncolytic VACV WR/TK30 (Western Reserve strain of VACV400 Molecular Therapy: Oncolytics Vol. 22 September 2021with a deleted thymidine kinase gene) by in-
activating a set of viral genes involved in
interfering with the IRF3 signaling pathway.
Three genes were selected for deletion: C6L,
N2L, and C10L. C6 interacts with the scaffold
proteins NAP1, TANK, and SINTBAD;31,32
N2 inhibits nuclear IRF3;33 and C10 (named
C16 in the WR strain) inhibits DNA-PK-
mediated DNA sensing.34,35 These genes
were sequentially deleted, and Figure 1A
schematically depicts deletions present in
the genomes of the viruses tested in this study
(WR/TK/D, WR/TK/2D, and WR/TK/
3D). Correct genetic modifications of the viral
genomes were confirmed by PCR analysis
with oligonucleotide primers flanking the
deletion sites (Figure 1B) and by sequencing.In addition, the whole genome of WR/TK/3D was sequenced,
confirming that no further mutations could have affected the on-
colytic capacity of the virus.
Deletion of genes blocking the IRF3 pathway do not interfere
with oncolytic VACV in vitro features
Maintaining an efficient replication of the vector virus in cancer cells
is important for achieving an effective oncolytic activity. Therefore,
we evaluated whether the deletions or the combinations of deletions
in the viral genomes have an influence on VACV replication in hu-
man cancer cells. For one-step growth or multiple-step growth anal-
ysis, we infected HeLa cells with candidate viruses at multiplicities of
infection (MOIs) of 5 or 0.05 and, at indicated time points, cultures
were harvested to determine viral titers by plaque assay. Both under
one-step growth (Figure 2A; Figures S1A or S1C) or multiple-step
growth conditions (Figure 2B), all candidate viruses replicated to ti-
ters similar to those obtained with the parental WR/TK virus. In
addition, replication was tested in A549 cells, a tumor cell line
described to retain intact IFN pathways.36,37 Again, the triple deletion
mutant virus combining C10L, N2L, and C6L gene deletions effi-
ciently grew in this cancer cell line, showing no difference in viral
progeny production compared to the WR/TK control virus
(Figure S2).
Figure 2. Unimpaired replication and capacity to kill cancer cells of mutant VACV accumulating deletions in genes inhibiting the IRF3 signaling pathway
(A and B) Productive multiplication of deletion mutant viruses. HeLa cells were infected with a multiplicity of infection (MOI) of 5 (A) or 0.05 (B) and, at indicated time points,
samples were collected and viral titers were determined by a plaque assay. Virus yield was evaluated in quadruplicate. (C) Plaque size analysis in MA104 cells. MA104 cell
monolayers were infected at an MOI of 0.05 and, at 72 h post-infection, stained with crystal violet solution before the diameter of plaques was measured. The diameter size
(mm) of 25 representative plaques per virus andmean ± SD are depicted. (D) Comparative cytotoxicity in human andmouse tumor cell lines. Cells were infected with indicated
viruses at doses ranging from 200 to 0.0001 PFU/cell. After 72 h, the percentage of killed cells was determined. *p < 0.05 versus WR/TK. ns, not significant.
www.moleculartherapy.orgThe size of virus plaques formed in cell monolayers after infection can
serve as an indicator of the viral capacity to destroy target cells upon
propagation. In MA104 cells, a cell line supporting the formation of
distinct plaque lesions upon VACV infection, the plaques obtained
after infection with the candidate viruses were not significantly
different in size compared to those formed after infection with WR/
TK, although we observed a tendency for plaque size reduction
with the accumulation of genomic deletions (Figure 2C).
To confirm the unimpaired capacity of candidate oncolytic viruses to
kill cancer cells, we assessed their efficacy in destroying tumor cells by
a metabolic assay. We infected both human (HeLa) andmouse cancercell lines (Renca and B16) with different MOIs (ranging from 0.0001
to 200) and, 72 h after infection, the remaining metabolic activity of
cells was determined (Figure 2D; Figures S1B and S1D). The capacity
to kill cancer cells was not affected by the accumulation of gene dele-
tions and resulted in very similar patterns of cell death for infections
with WR/TK/D, WR/TK/2D, and WR/TK/3D compared to the
parental virus WR/TK.
Deletionof viralgenes interferingwith the IRF3signalingpathway
leads to phosphorylation of IRF3 and expression of IFN-b
To evaluate whether infection with candidate oncolytic VACV (WR/
TK/D, WR/TK/2D, and WR/TK/3D) leads to activation of theMolecular Therapy: Oncolytics Vol. 22 September 2021 401
Figure 3. Activation of the IRF3 pathway by candidate oncolytic VACV
(A and B) Deletion of viral genes interfering in the IRF3 pathway leads to IRF3 phosphorylation in human cells. HeLa (A) and THP-1 (B) cells were infected at an MOI of 10 and,
5 h after infection, cells were lysed and western blot analysis was performed using a monoclonal antibody against p-IRF3. The non-replicating VACV MVA (modified vaccinia
virus Ankara) served as a positive control and GAPDH-specific immunoblotting served as a loading control. (C and D) Detection of IFN-bmRNA by RT-PCR in human cells.
HeLa (C) and THP-1 (D) cells were infected at anMOI of 5. At 6 h after infection, total RNAwas obtained andmRNAs of indicated genes were amplified by RT-PCR. The VACV
E3LmRNAwas used as an infection control, and GAPDHmRNAwas used as a loading control. (E) Relative expression of IFN-bmeasured by qRT-PCR. Indicated cells were
infected with WR/TK or WR/TK/3D, and total RNA was obtained as indicated in (C) and (D). mRNA expression levels of IFN-b were determined via qRT-PCR and
normalized to that of the GAPDH gene by the 2DDCt. **p < 0.01, ***p < 0.001.
Molecular Therapy: OncolyticsIRF3 pathway, we determined the amounts of phosphorylated IRF3
(p-IRF3) by western blot after infection of human cancer cells. As a
positive control for the activation of the IRF3 pathway, we used infec-
tions with the replication-deficient MVA, which is a natural VACV
mutant with many inactivated viral genes and is known to efficiently
activate IRF3.38 In HeLa cells, levels of p-IRF3 were not increased by
the presence of deletions compared to the parental virus WR/TK
(Figure 3A). However, in THP-1 cells (a human monocyte cell line
broadly used for immune assay experiments, Figure 3B) we detected402 Molecular Therapy: Oncolytics Vol. 22 September 2021increasing amounts of p-IRF3 upon infection with viruses harboring
accumulating inactivation in genes interfering with the IRF3 pathway.
In addition, phosphorylation of IRF3 after infection of mouse cancer
cell lines was also evaluated. In B16 cells (Figure S3A), a clear
tendency to detect increasing levels of p-IRF3 was observed with
accumulation of deletions, similar to THP-1 cells. In Renca cells, no
phosphorylated protein was detected even for the MVA-positive con-
trol (Figure S3B). Effects of single gene deletions were discarded by
western blot analysis of extracts from THP1 cells infected with
Figure 4. Replication of deletion mutant VACV in tumor models in vivo
5 105 Renca cells were subcutaneously implanted on the flank of 6- to 8-week-old
BALB/c mice (n = 4–5). At day 0, a dose of 1 107 PFU was intratumorally injected
and, 4 days later, mice were sacrificed and tumors were harvested. (A) Images of
representative tumors showing mCherry-specific fluorescence. (B) Tumor fluores-
cence quantified using a MacroImaging system. Fluorescence of individual tumors
and group means ± SD are shown. (C) Viral titers determined by plaque assay after
tumor homogenization. Titers obtained from each independent tumor and means ±
SD are depicted. *p < 0.05. ns, not significant.
www.moleculartherapy.orgmutant viruses, including all possible combinations of C10L, N2L,
and C6L gene deletions (Figure S3E).
IRF3 activation was confirmed by RT-PCR. We detected increased
levels of IFN-b mRNA upon infection with the WR/TK/3D virus
(Figures 3C and 3D; Figures S3C and S3D). Of note, this finding in-cludes HeLa and Renca cells (Figure 3D; Figure S3D), where increased
levels of p-IRF3 protein could not be detected by immunoblot anal-
ysis. Quantification of IFN-b mRNA by qRT-PCR demonstrated a
significant increase mediated by the WR/TK/3D virus compared
to the levels activated by the WR/TK control virus (Figure 3G).
Replication of deletion mutant viruses is not impaired in mouse
tumor models
To ensure that virus replication remains unimpaired in vivo, we in-
jected mice bearing Renca tumors (mouse renal adenocarcinoma) in-
tratumorally with the candidate deletion mutant viruses and, 4 days
after virus injection, viral growth was evaluated. Taking advantage
of mCherry co-expression (Figure 1A), fluorescence emitting from
tumor tissues was quantified (Figures 4A and 4B). In addition, we
titrated the virus loads within tumors (Figure 4C). Both methodolog-
ical approaches showed that deletion mutant viruses and the parental
virus WR/TK replicated to very similar levels in tumor tissues. This
indicates that deletion of up to three genes interfering with the IRF3
pathway does not hinder effective VACV replication, both in vitro
and in vivo.
Improved antitumor activity of oncolytic candidate VACV
As a next step, we evaluated the antitumor efficacy of the deletion
mutant VACV in vivo using intratumoral virus delivery in two synge-
neic mouse tumor models: BALB/c mice bearing Renca tumors and
C57BL/6 mice bearing B16 tumors. In the Renca model, the injection
of WR/TK/2D or WR/TK/3D viruses resulted in a strong signifi-
cant reduction of tumor growth in comparison to the therapeutic ef-
fect observed with the parental WR/TK (Figure 5A; Figure S4A).
Additionally, we also observed an increased survival time of mice in-
jected with double and triple deletion mutant VACV (Figure 5B).
When tested in themouse melanoma tumormodel B16, and although
some mice needed to be sacrificed early in the experiment due to tu-
mor ulceration (Figure S4B), the WR/TK/3D virus was able to
induce a significant reduction in tumor growth (Figure 5C), but
this was not the case with the WR/TK/2D virus. The survival
time of this model is shown in Figure 5D. MVA was not included
as a control in these experiments, as the antitumor activity of this vi-
rus is limited by its incapacity to productively replicate in tumor cells
when compared to WR/TK.26
Induction of tumor-specific cellular immune response by
deleted VACVs
Our hypothesis was that increased antitumor activity of deleted
VACV is mediated by increased type I IFN levels within tumors,
which leads to a more robust cellular antitumor immunity. Thus,
we tested the IFN-b concentration within tumors by ELISA 4 days af-
ter virus administration. We detected a 2-fold increase in IFN-b levels
in tumors injected with WR/TK/3D compared to those injected
with WR/TK, although the difference was not significant (Fig-
ure 6A). Finally, we evaluated the tumor epitope-specific T cell re-
sponses established following virus administration in the B16 tumor
model. Enzyme-linked immunospot (ELISPOT) assays were per-
formed to determine the T cell response directed against the virusMolecular Therapy: Oncolytics Vol. 22 September 2021 403
Figure 5. Increased in vivo antitumor activity of
candidate oncolytic VACV with combination of gene
deletions rescuing IRF3 activation
(A–D) 5  105 tumor cells were subcutaneously implanted at
day 9 on the flank of 6- to 8-week-old BALB/c mice (Renca
tumors, A and B) or C57BL/6 mice (B16 tumors, C and D),
and viruses were intratumorally administered at days 0 and 4
at a dose of 1 107 PFU/injection. PBS-injected mice served
as controls. For monitoring tumor growth, the tumors were
measured two to three times per week until termination
criteria were reached. Tumor volume (A and C) and overall
survival (B and D) are plotted for 7–9 mice/group ± SEM. *p <
0.05, **p < 0.01, ***p < 0.001.
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Figure 6. Intratumoral administration of deletion mutant VACV induces antitumor T cell responses directed against tumor neo-antigens
(A) Intratumoral IFN-b concentrations after mutant VACV injection. BALB/c mice harboring Renca tumors were treated with a single intratumoral dose of 1  107 PFU and,
4 days later, tumors were harvested and homogenized. IFN-b concentrations were determined by an ELISA. (B) Cellular immune response evaluated by an IFN-g ELISPOT
assay. C57BL/6 mice harboring B16 tumors were treated as indicated in Figure 5, and, 8 days after virus administration, splenocytes were prepared, in vitro stimulated with
indicated peptides, and analyzed for IFN-g-producing cells by ELISPOT. Individual values of IFN-g spot forming cells (SPC)/105 splenocytes in 4–5 mice/group and mean ±
SD are plotted. *p < 0.05. ns, not significant.
www.moleculartherapy.org(immunodominant VACV-specific B8R peptide epitope),39 a non-
mutated gp100 tumor-associated antigen epitope,40 and the tumor
neo-epitope B16-M30.41 The injection of WR/TK/3D increased
T cell reactivity to all the three epitopes (Figure 6B); however, of
note, we found clearly increased levels of epitope-specific IFN-g-pro-
ducing T cells directed against the tumor antigens (gp100 and B16-
M30) compared to treatments with the parental virus WR/TK.
DISCUSSION
Our goal in this work was to obtain a fully replication-competent on-
colytic VACV with improved capacity to activate antitumor T cell re-
sponses. The replication of oncolytic VACV in cancer cells leads to
the release of danger-associated molecular patterns (DAMPs)
together with a multitude of tumor-specific antigens, turning “cold”
tumors into “hot” tumors for more efficacious immunotherapy.42
We based our strategy for improving antitumor T cell responses on
the observation that poly(I:C), used as an adjuvant in cancer vaccina-
tion, leads to T helper 1 (Th1) polarization,43 which directly correlates
with robust antitumor immunity in the clinic.44 As poly(I:C) selec-
tively activates TLR3, we attempted to construct an oncolytic vector
virus with the capacity to activate the TLR3-IRF3 pathway after
infection.
In line with its outstanding capacity to evade antiviral innate immu-
nity, VACV encodes for several immunomodulatory proteins directly
interfering with the host TLR3-IRF3 innate response pathway. In or-
der to promote the activation of this pathway, we constructed a series
of oncolytic VACVs combining the deletion of the thymidine kinase
gene (to achieve selective replication in cancer cells) with targeted
inactivation of selected genes interfering with IRF3 pathway activa-
tion. We chose three target proteins due to their important inhibitory
mechanisms at different levels in the pathway: C10 (also known as
C16 due to its nomenclature in the Western Reserve strain) preventsdouble-stranded DNA (dsDNA) recognition by DNA-PK;34,35 N2 in-
terferes by yet unknown mechanisms downstream of p-IRF3 and its
nuclear translocation;33 and C6 interacts with NAP1, TANK, and
SINTBAD, the scaffold adaptor proteins for the kinases TBK1 and
IKKε, which lead to IRF3 activation.31,32 We constructed all of the
possible mutant VACVs combining deletions in these three genes,
but one single-, one double-, and the triple-deletion mutant viruses
were selected for complete testing; the selection was performed based
on the lack of loss in cytotoxicity and the replicative capacity in vitro
(Figure S1). Deletions included in the final candidate oncolytic VACV
are depicted in Figure 1. As shown in Figure 2 and Figure S2, inclusion
of up to three of these mutations does not impair the capacity of
VACV to replicate in cancer cells or their cancer cell-killing efficacy
in vitro.
Combination of deletions in C10L, N2L, and C6L genes results in
activation of the TLR3-IRF3 pathway as demonstrated by detection
of p-IRF3 and IFN-b mRNA (Figure 3; Figure S3). Increasing levels
were detected by the introduction of deletions to the genome of the
control virus WR/TK, and Figure S3E shows that this activation
is mediated by this accumulation of deletions rather than by any of
the single deletions. In mouse models, this TLR3-IRF3 pathway
activation translates into increased intratumoral IFN levels (Fig-
ure 6A) and improved T cell responses, both directed against the
virus and the tumor (Figure 6B). Importantly, anti-tumor T cells
are directed against tumor-associated antigens (gp100) but also
against tumor neo-epitopes (B16-M30), and T cell activities elicited
by WR/TK/3D are significantly higher as compared with re-
sponses obtained with the non-treated group. Finally, these
enhanced tumor-directed immune responses are associated with
an improved antitumor activity in two syngeneic mouse tumor
models (Figure 5), strongly suggesting the feasibility and efficacy
of the proposed strategy.Molecular Therapy: Oncolytics Vol. 22 September 2021 405
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the TLR3-IRF3 signaling pathway) also explored the strategy of acti-
vating the TLR3-IRF3 pathway after infection of tumor cells.30 This
virus demonstrated a switch from a Th2- to a Th1-skewed response
and displayed enhanced therapeutic activity in mouse models. How-
ever, replication of the virus was strongly hindered within tumors (us-
ing the Renca model) due to massive pathway activation; conversely,
our novel strategy of accumulating up to three deletions in VACV
genes interfering with the TLR3-IRF3 pathway fully conserved the
replication capacity in Renca tumors (Figure 4). We have previously
demonstrated the importance of VACV replication for activating an
antitumor immune response,26 which is discrepant to some previous
reports.45 Yet, virus replication leads to tumor cell lysis and release of
tumor antigens, in addition to amplifying the initial dose adminis-
tered and multiplying danger signals. Thus, maintaining an efficient
replication in tumor cells is a key factor for the outcome of oncolytic
therapies and should be an important feature when developing a
candidate for clinical evaluation.
Although able to improve antitumor immune responses, levels of p-
IRF3 and IFN-bmRNAdetected after infection withWR/TK/3D do
not reach the levels observed after infection with MVA (Figure 3; Fig-
ure S3). Previously, VACV incorporating single deletions in the C6L,
N2L, or C10L gene demonstrated enhanced immunogenicity and
highly reduced virulence in mice.22,33,46 However, we were unable
to detect TLR3-IRF3 pathway activation in vitro after infection with
any of these three single deleted VACVs (Figure S3E). Thus, activities
detected in in vitro assays may not properly reflect levels of activation
in vivo in animal models. Currently, we are working on incorporating
further deletions into our WR/TK/3D candidate virus to test the
possibility to further improve this activation. Additional VACV reg-
ulatory proteins with inhibitory functions in activation of the TLR3-
IRF3 signaling pathway include A46, which interacts with TRIF,47 K7,
which binds the DEAD-box RNA helicase 3 (DDX3),48 and B19 (also
known as B18 due to its nomenclature in theWestern Reserve strain),
which is a soluble type I IFN receptor.49 Recently, the VACV B2R
gene has been reported to encode a viral nuclease with cyclic guano-
sine monophosphate-AMP (cGAMP)-specific activity and an impor-
tant role in the inhibition of the pathway.50 However, further
deletions incorporated to the WR/TK/3D virus may compromise
the ability of these deletion mutant viruses to efficiently replicate in
cancer cells, as demonstrated by the growth deficiency of the natural
deletion mutant virus MVA. An appropriate balance between the
activation of danger signaling pathways and virus replication must
be found for optimizing oncolytic VACV immunotherapies.
Taken together, the data presented herein demonstrate that it is
possible to generate an oncolytic VACV with the ability to activate
the TLR3-IRF3 pathway while maintaining full capacity to produc-
tively replicate in cancer cells. Importantly, the combination of these
features translates into improved antitumor immunity and antitumor
efficacy of the oncolytic vector virus. This strategy can be combined
with other genetic modifications or immunotherapies to produce
robust responses in patients suffering from a variety of solid tumors.406 Molecular Therapy: Oncolytics Vol. 22 September 2021MATERIALS AND METHODS
Cell lines and viruses
All cell lines used in this research (MA104,HeLa, Renca, B16, andTHP-
1 cells) were obtained from the American Type Culture Collection
(ATCC). Primary chicken embryo fibroblasts (CEFs) were prepared
from 10-day-old chicken embryos (specific pathogen-free [SPF] eggs,
VALO BioMedia, Cuxhaven, Germany). All cell lines were maintained
in recommended culturemedia containing 5%–10% fetal bovine serum
and antibiotics at 37C, 5% CO2.
All recombinant viruses used or constructed in thiswork, except for the
MVAcontrol virus, are based on theVACVstrainWesternReserve. To
enhance selective replication in cancer cells, VACVWR/TKwas con-
structed by inactivation of the viral thymidine kinase gene through
insertion of an expression cassette for themCherry reporter gene under
transcriptional control of the VACV late promoter P11. VACV WR/
TK served as the backbone for deleting the targetVACVgenes block-
ing the IRF3 pathway activation. The C6L, C10L, and N2L genes were
inactivated by homologous recombination replacing the original gene
sequence with a synthetic construct containing two 350-bp DNA se-
quences upstream and downstream of the genomic site targeted for
deletion. In addition, the start codon in the synthetic target gene
sequencewasmutated. Forhomologous recombination andgeneration
of the VACV deletion mutants, a shuttle plasmid DNA containing the
synthetic gene sequence (DC6L,DC10L, orDN2L) was transfected into
MA104 cells that were infected with VACVWR/TK 90 min prior to
plasmid transfection. The deletion mutants were clonally isolated by a
positive-negative selection system based on GFP as a reporter, and all
genetic modifications were confirmed by PCR and sequencing. For the
construction of mutant viruses with accumulating gene deletions, the
homologous recombination process was repeatedwith a different shut-
tle plasmid once the first deletionwas confirmed. Viruses were purified
as previously described26 and titrated by a plaque assay inMA104 cells
(for replication-competent VACV) or in CEF cells (for the MVA
strain). The whole-genome sequences of the WR/TK and WR/
TK/3D viruses were determined and analyzed using MinION tech-
nology (Laboratory for FunctionalGenomeAnalysis, LMU,Germany).Virus growth assay and plaque size
2  105 cells were seeded in 24-well plates and infected at an MOI
(plaque-forming units [PFU]/cell) of 5 or 0.05. One hour after infec-
tion, cells were washed with PBS and new pre-warmed medium was
added. At different time points (0, 4, 12, 24, 48, and 72 h after infec-
tion), samples were harvested and frozen at 80C. Viral titer was
determined by a plaque assay after three freeze-thaw-cycles.
To assess the size of the plaques formedby the different viruses,MA104
cells were infected at an MOI of 0.05 and, at 72 h post-infection, the
diameter of plaques was measured after dying with crystal violet.In vitro cytotoxicity assay
Cytotoxicity assays were performed by seeding 5 104 cells in 96-well
plates. Cells were infected with 1:5 serial dilutions starting at an MOI
www.moleculartherapy.orgof 150 (ranging from 150 to 0.0001) and incubated at 37C for 72 h.
After 3 days, cells were checked for remainingmetabolic activity using
a non-radioactive cell proliferation assay (CellTiter 96 AQueous non-
radioactive cell proliferation assay, Promega, Fitchburg, WI, USA)
following the manufacturer’s instructions.
Protein analysis
Indicated cells were seeded in 24-well plates and infected at an MOI of
10. 5 h after infection, cells were harvested and lysed using radioimmu-
noprecipitation (RIPA) assay buffer supplemented with 1% protease/
phosphatase inhibitor cocktail (Thermo Scientific, Waltham, MA,
USA). Protein extracts were quantified by a bicinchoninic acid
(BCA) assay kit, and equal amounts of protein were separated by
10% SDS gel and transferred to a nitrocellulose blottingmembrane. Af-
ter blocking the membrane with Tris-buffered saline (TBS)/Tween 20
with 5%BSA, amonoclonal anti-p-IRF3 primary antibody (S396 rabbit
monoclonal antibody [mAb],Cell SignalingTechnology,Danvers,MA,
USA) diluted 1:1,000 in TBS/Tween 20 with 1% BSA and a polyclonal
anti-rabbit conjugated with horseradish peroxidase (HRP) (Cell
Signaling Technology, Danvers, MA, USA) diluted 1:5,000 in TBS/
Tween 20with 1%BSAwere used for detection. For the loading control,
a rabbit anti-GAPDH antibody (Cell Signaling Technology, Danvers,
MA, USA) diluted 1:1,000 in TBS/Tween 20 with 1% BSA was used.
mRNA expression analysis
1  106 cells/well were seeded in 24-well plates and infected at an
MOI of 5. At 6 h post-infection, cells were harvested and total RNA
was purified using a RNeasy Plus mini kit (QIAGEN, Hilden, Ger-
many). To eliminate remaining genomic DNA, samples were digested
with RQ1 RNase-free DNase (Promega, Madison, WI, USA). cDNA
was synthesized using an Omniscript RT kit (QIAGEN, Hilden, Ger-
many), and the PCR was performed on 1.5 mg of cDNA using specific
primers for the mRNA of interest and run in an agarose gel.
For qRT-PCR analysis, cDNA samples were obtained as described
above, and qRT-PCR was performed using the Luna universal qPCR
master mix (New England Biolabs, Ipswich, MA, USA) under the
following conditions: initial denaturation at 95C for 1 min, followed
by 42 cycles of 95C for 15 s, 60C for 30 s, followed by melting curve
at 65C –95C, 0.5C/cycle. TheAriaMx real-timePCR system (Agilent
Technologies, Santa Clara, CA, USA) and the corresponding Aria 1.7
software were used to perform and analyze the qPCRs. Relative expres-
sions of IFN-b were normalized to those of GAPDH, using the 2DDCt
method.51 The following primers, whichwere previously described,52,53
were used: human (h)IFN-b forward, 50-GCTTGGATTCCTACAAA-
GAAGCA-30, reverse, 50-ATAGATGGTCAATGCGGCGTC-30; hGA
PDH forward, 50-ATTTGGCTACAGCAACAGG-30, reverse, 50-TTG
AGCACAGGGTACTTTATT-30.
Mouse models
All animal experiments were handled in compliance with the German
regulations for animal experimentation (Animal Welfare Act,
approved by the Government of Upper Bavaria, Munich, Germany).
6- to 8-week-old female BALB/c (Renca tumor model) or C57BL/6(B16 tumor model) mice were purchased from Charles River Labora-
tories and housed in an isolated (ISO) cage unit with free access to
food and water. Tumor cells for implantation were maintained
in vitro at standard conditions. At the day of implantation, cells
were trypsinized and 5  105 cells were implanted in the flank of
the mice. When tumors reached a volume of 50–100 mm3, mice
were randomized and viruses were administrated intratumorally.
Study of viral replication and IFN-b quantification in vivo
Tumors were established as described above. After randomization of
mice (n = 4–6), they received at day 0 a single intratumoral dose of
1  107 PFU. Mice were sacrificed at day 4 and tumors were har-
vested, washed with PBS, and the fluorescence signal from tumors
was acquired using a GelDoc imaging system (Bio-Rad, Hercules,
CA, USA) and quantified using ImageJ.
For determining viral titer and IFN-b concentrations within tumors,
mice were treated as described above and sacrificed at day 4 after viral
administration. Tumors were harvested, weighed, and homogenized
using metal beads and a tissue homogenizer (QIAGEN, Hilden, Ger-
many). Virus titers were determined by plaque assay on MA104 cells,
and IFN-b was quantified using a mouse IFN-b ELISA kit (R&D Sys-
tems, Minneapolis, MN, USA).
In vivo antitumor activity
Tumors were established as described above. Mice were treated twice
(days 0 and 4) with an intratumoral dose of 1 107 PFU of indicated
viruses. Mice were monitored daily, tumors were measured 3 times
per week using a caliper, and tumor volume was calculated as the
length width height in mm3. Mice were euthanized when tumors
reached termination criteria.
IFN-g ELISPOT
Tumors were established as described above, and mice were treated
twicewith an intratumoral dose of indicated viruses. 5 days after the sec-
ond virus injection, mice were sacrificed and spleens harvested. 2 105
cells were cultured for 48 h in anti-IFN-g (Mabtech, Stockholm, Swe-
den)pre-coated 96-well plates togetherwith 2mg/mLpeptides. The syn-
thetic peptides used for restimulation were B8R (TSYKFESV), gp100
(EGSRNQDWL), and B16-M30mut (PSKPSFQEFVDWENVSPEL
NSTD). An automated ELISPOT reader (A.EL.VIS Eli.Scan,Hannover,
Germany) was used for counting and analyzing.
Statistical analysis
A standard Student’s t test (two-tailed) was used for analyzing results
in Figures 2 and 3G and Figure S1. A one-way ANOVA and Tukey’s
multiple comparison test was used for analyzing Figures 4 and 6. In
Figure 5, a two-way ANOVA and Bonferroni posttest were chosen
for analyzing tumor growth curves, and a log-rank test was used for
survival curves. In all cases, significance was achieved when p < 0.05.
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